These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 20736151)

  • 1. Impact of baseline antiretroviral resistance status on efficacy outcomes among patients receiving maraviroc plus optimized background therapy in the MOTIVATE 1 and 2 trials.
    Nelson M; Fisher M; Gonzalez-Garcia J; Rockstroh JK; Weinstein D; Valdez H; Mayer H; van der Ryst E; Goodrich JM; Dang N
    HIV Clin Trials; 2010; 11(3):145-55. PubMed ID: 20736151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maraviroc for previously treated patients with R5 HIV-1 infection.
    Gulick RM; Lalezari J; Goodrich J; Clumeck N; DeJesus E; Horban A; Nadler J; Clotet B; Karlsson A; Wohlfeiler M; Montana JB; McHale M; Sullivan J; Ridgway C; Felstead S; Dunne MW; van der Ryst E; Mayer H;
    N Engl J Med; 2008 Oct; 359(14):1429-41. PubMed ID: 18832244
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
    Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
    Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection.
    Fätkenheuer G; Nelson M; Lazzarin A; Konourina I; Hoepelman AI; Lampiris H; Hirschel B; Tebas P; Raffi F; Trottier B; Bellos N; Saag M; Cooper DA; Westby M; Tawadrous M; Sullivan JF; Ridgway C; Dunne MW; Felstead S; Mayer H; van der Ryst E;
    N Engl J Med; 2008 Oct; 359(14):1442-55. PubMed ID: 18832245
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of optimized background therapy plus maraviroc for previously treated patients with R5 HIV-1 infection from the perspective of the Spanish health care system.
    Moreno S; González J; Lekander I; Martí B; Oyagüez I; Sánchez-de la Rosa R; Casado MA
    Clin Ther; 2010 Dec; 32(13):2232-45. PubMed ID: 21316539
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and immunovirologic outcomes with maraviroc combination regimens in patients with a history of past treatment failures and virologic resistance in Brazil: an open-label, multicenter phase 3b study.
    Furtado J; Madruga JV; Bicudo EL; da Eira M; Lopes MI; Netto EM; Santini-Oliveira M; Leite OH; Machado AA; Tupinambas U; de Andrade Neto JL; Lima MP; Pedro Rde J; Miranda AF; Lewi DS; Santos BR; Portsmouth S; Wajsbrot DB; Cassoli LM
    AIDS Res Hum Retroviruses; 2013 Sep; 29(9):1203-10. PubMed ID: 23731330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1.
    Saag M; Goodrich J; Fätkenheuer G; Clotet B; Clumeck N; Sullivan J; Westby M; van der Ryst E; Mayer H;
    J Infect Dis; 2009 Jun; 199(11):1638-47. PubMed ID: 19432546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
    Ndegwa S
    Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Maraviroc.
    Carter NJ; Keating GM
    Drugs; 2007; 67(15):2277-88; discussion 2289-90. PubMed ID: 17927288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiretroviral-Experienced HIV-1-Infected Patients Treated with Maraviroc: Factors Associated with Virological Response.
    Soulie C; Peytavin G; Charpentier C; Lambert-Niclot S; Sayon S; Visseaux B; Simon A; Katlama C; Yazdanpanah Y; Descamps D; Calvez V; Marcelin AG
    AIDS Res Hum Retroviruses; 2015 May; 31(5):475-8. PubMed ID: 25420695
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Two-year safety and virologic efficacy of maraviroc in treatment-experienced patients with CCR5-tropic HIV-1 infection: 96-week combined analysis of MOTIVATE 1 and 2.
    Hardy WD; Gulick RM; Mayer H; Fätkenheuer G; Nelson M; Heera J; Rajicic N; Goodrich J
    J Acquir Immune Defic Syndr; 2010 Dec; 55(5):558-64. PubMed ID: 20703158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Maraviroc efficacy in clinical studies on the development of the molecule].
    Moreno S; Hernández B; Gutiérrez C; Delsol E
    Enferm Infecc Microbiol Clin; 2008 Oct; 26 Suppl 11():17-22. PubMed ID: 19133217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Real-life outcomes of maraviroc-based regimens in HIV-1-infected individuals.
    Babiker ZO; Douthwaite ST; Collier LE; Pennell A; Uriel AJ; Wilkins E
    J Int Assoc Provid AIDS Care; 2013; 12(1):12-4. PubMed ID: 23076664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of adding maraviroc to antiretroviral regimens in patients with full viral suppression but impaired CD4 recovery.
    Stepanyuk O; Chiang TS; Dever LL; Paez SL; Smith SM; Perez G; Eng RH
    AIDS; 2009 Sep; 23(14):1911-3. PubMed ID: 19584703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Switching the third drug of antiretroviral therapy to maraviroc in aviraemic subjects: a pilot, prospective, randomized clinical trial.
    Bonjoch A; Pou C; Pérez-Álvarez N; Bellido R; Casadellà M; Puig J; Noguera-Julian M; Clotet B; Negredo E; Paredes R
    J Antimicrob Chemother; 2013 Jun; 68(6):1382-7. PubMed ID: 23354282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A microsimulation of the cost-effectiveness of maraviroc for antiretroviral treatment-experienced HIV-infected individuals.
    Kühne FC; Chancellor J; Mollon P; Myers DE; Louie M; Powderly WG
    HIV Clin Trials; 2010; 11(2):80-99. PubMed ID: 20542845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection.
    Cooper DA; Heera J; Goodrich J; Tawadrous M; Saag M; Dejesus E; Clumeck N; Walmsley S; Ting N; Coakley E; Reeves JD; Reyes-Teran G; Westby M; Van Der Ryst E; Ive P; Mohapi L; Mingrone H; Horban A; Hackman F; Sullivan J; Mayer H
    J Infect Dis; 2010 Mar; 201(6):803-13. PubMed ID: 20151839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Maraviroc.
    Fadel H; Temesgen Z
    Drugs Today (Barc); 2007 Nov; 43(11):749-58. PubMed ID: 18174962
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study.
    Sierra-Madero J; Di Perri G; Wood R; Saag M; Frank I; Craig C; Burnside R; McCracken J; Pontani D; Goodrich J; Heera J; Mayer H
    HIV Clin Trials; 2010; 11(3):125-32. PubMed ID: 20736149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of R5 strains in multi-treated HIV subjects and impact of new regimens including maraviroc in a selected group of patients with CCR5-tropic HIV-1 infection.
    Bon I; Clò A; Borderi M; Colangeli V; Calza L; Morini S; Miserocchi A; Cricca M; Gibellini D; Re MC
    Int J Infect Dis; 2013 Oct; 17(10):e875-82. PubMed ID: 23597487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.